P-170 GLYCOPROTEIN, GLUTATHIONE AND ASSOCIATED ENZYMES IN RELATION TO CHEMORESISTANCE OF PRIMARY HUMAN RENAL-CELL CARCINOMAS

被引:26
作者
MICKISCH, G
BIER, H
BERGLER, W
BAK, M
TSCHADA, R
ALKEN, P
机构
[1] ENT, Mannheim Hospital, University of Heidelberg, FRG
[2] Department of Cell Biology, Institute of Experimental Pathology, German Cancer Research Center, Heidelberg, FRG
关键词
Glutathione; Human renal cell carcinoma; Multidrug resistance; P-170; glycoprotein;
D O I
10.1159/000281701
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
High intrinsic chemoresistance contributes to the dismal outcome of patients with disseminated renal cell carcinoma (RCC). In experimental cell lines, two defined defence mechanisms, P-170 glycoprotein and glutathione metabolism, have been established in multidrug resistance, a cross-resistance to cytotoxic compounds without functional or structural similarities. In 21 primary human RCCs, P-170 expression was examined, glutathione content and activities of related enzymes determined and the results were correlated to the degree of in vitro chemoresistance. P-170 was found in 10 of 17 resistant tumors but in none of the sensitive cases. The glutathione content was significantly higher and the related enzyme distinctively enhanced in resistant RCCs. Both mechanisms occurred independently and may well explain the multidrug resistance of RCC. Therefore, reversal of one or both systems may have a clinical impact on the chemotherapy of RCCs. © 1990 S. Karger AG, Basel.
引用
收藏
页码:170 / 176
页数:7
相关论文
共 35 条
[21]  
Ellman G.L., Tissue sulfhydryl groups, Arch Biochem Biophys, 82, pp. 70-77, (1958)
[22]  
Shen D.W., Cardarelli C., Hwang J., Et al., Multiple drug resistant human KB carcinoma cells independently selected for high level resistance to colchicine, adriamycin or vinblastine, show changes in expression of specific proteins, J Biol Chem, 261, pp. 7762-7770, (1986)
[23]  
Arrick B.A., Nathan C.F., Gluthatione metabolism as a determinant of therapeutic efficacy, Cancer Res, 44, pp. 4224-4232, (1984)
[24]  
Tsuruo T., Mechanisms of multidrug resistance and implication for therapy, Jap J Cancer Res, 79, pp. 285-296, (1988)
[25]  
Pastan I., Gottesman M.M., Multiple drug resistance in human cancer, N Engl J Med, 316, pp. 1388-1393, (1987)
[26]  
Hamada H., Tsuruo T., Functional role for the 170 to 180 kDA glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies, Proc Natl Acad Sci USA, 83, pp. 7785-7789, (1986)
[27]  
Fojo A.T., Akiyama S., Gottesman M.M., Et al., Reduced drug accumulation in multiple drug resistant human KB carcinoma cell lines, Cancer Res, 45, pp. 3002-3007, (1985)
[28]  
Sugarawa I., Kataoka I., Morishita Y., Et al., Tissue distribution of P-glycoprotein encoded by a multidrug resistant gene as revealed by a monoclonal antibody, MRK 16, Cancer Res, 48, pp. 1926-1929, (1988)
[29]  
Kakehi Y., Kanamaru H., Yoshida O., Et al., Measurement of multidrug resistance messenger RNA in urogenital cancers: Elevated expression in renal cell carcinoma is associated with intrinsic drug resistance, J Urol, 139, pp. 862-865, (1988)
[30]  
Sies H., Wendel A., Functions of Glutathione in Liver and Kidney, (1978)